Optimizing Treatment of Parkinson's Disease.


Journal

Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269

Informations de publication

Date de publication:
09 Feb 2022
Historique:
received: 04 02 2022
accepted: 05 02 2022
entrez: 25 2 2022
pubmed: 26 2 2022
medline: 26 2 2022
Statut: epublish

Résumé

The holy grail of therapy in Parkinson's disease (PD) is treatment that would halt the disease process or restore the degenerated neuronal circuits [...].

Identifiants

pubmed: 35207734
pii: jpm12020245
doi: 10.3390/jpm12020245
pmc: PMC8880050
pii:
doi:

Types de publication

Editorial

Langues

eng

Références

J Pers Med. 2021 Jul 26;11(8):
pubmed: 34442364
J Pers Med. 2021 Jun 05;11(6):
pubmed: 34198780
J Pers Med. 2021 Jun 08;11(6):
pubmed: 34201198
J Pers Med. 2022 Jan 21;12(2):
pubmed: 35207632
J Pers Med. 2022 Jan 02;12(1):
pubmed: 35055343
J Pers Med. 2020 Nov 25;10(4):
pubmed: 33255761
J Pers Med. 2021 Jun 12;11(6):
pubmed: 34204708
J Pers Med. 2021 Mar 31;11(4):
pubmed: 33807308
J Pers Med. 2021 Nov 02;11(11):
pubmed: 34834488
J Pers Med. 2022 Jan 08;12(1):
pubmed: 35055390

Auteurs

Dag Nyholm (D)

Department of Medical Sciences, Neurology at Uppsala University, 75185 Uppsala, Sweden.

Filip Bergquist (F)

Department of Pharmacology, Institute of Neuroscience and Physiology, University of Gothenburg, 41296 Gothenburg, Sweden.

Classifications MeSH